Coronary Artery Disease
Conditions
Interventions
Treatment with rosuvastatin 20mg once daily (Treatment begins from 5mg/day)
Treatment with rosuvastatin 2.5mg once daily
Dietetic treatment and therapeutic exercise
Sponsors
Showa University Fujigaoka Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with provoked coronary artery spasm. Boundary high LDL cholesterolemia. (100<=LDL-C<=139mg/dL) Patient who agreed with document.
Exclusion criteria
Exclusion criteria: Patients who take statin already. Patients with familial hypercholesterolemia or secondary hyperlipidemia. Serum TG is 400mg/dL or more. Patients who have hypersensitivity for statin. Patients who have active liver disease. Patients who have renal dysfunction. Serum CK is 500IU/L or more. Patients who take cyclosporine. Pregnancy or possibility of pregnancy. Patients who have hypothyroidism, inherited stripe disease (muscular dystrophy etc.) or the family medical histories and patients who have previous history of medicinal muscle disorder. Patient of drug abuse or alcoholism. Additionally, patients who do not receive physician's approval.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of incidence of provoked coronary artery spasm at 6-month follow-up between Rosuvastatin group and control group | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of incidence of provoked coronary artery spasm at 6-month follow-up between Rosuvastatin high dose and low dose group and control group Relationship between lipid profiles and provoked coronary artery spasm rate Relationship between endothelial function and provoked coronary artery spasm rate Adverse events, side effect event | — |
Countries
Japan
Contacts
Public ContactKohei Wakabayashi
Showa University Fujigaoka Hospital Division of Cardiology
Outcome results
None listed